Focal Caspase Activation Underlies the Endplate Myopathy in Slow-Channel Syndrome

Annals of Neurology

Volumn 55, Issue 3, 2004, Pages 347-352

  Vohra, Bhupinder P S ^a,d   Groshong, Jason S ^a   Maselli, Ricardo A ^b   Verity, M Anthony ^c   Wollmann, Robert L ^e   Gomez, Christopher M ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; CASPASE; CATION; CHOLINERGIC RECEPTOR; CYSTEINE PROTEINASE; MUTANT PROTEIN;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; CASE REPORT; CELL DEATH; CELL ULTRASTRUCTURE; CELL VACUOLE; CLINICAL FEATURE; CONGENITAL MYASTHENIC SYNDROME; CONTROLLED STUDY; DISEASE COURSE; ELECTRON MICROSCOPY; ENDPLATE MYOPATHY; ENZYME ACTIVATION; EVIDENCE BASED MEDICINE; HUMAN; HUMAN TISSUE; IMMUNOLOCALIZATION; MITOCHONDRION; MUSCLE BIOPSY; MYOPATHY; NERVE CELL DEGENERATION; NEUROMUSCULAR DISEASE; NEUROMUSCULAR SYNAPSE; NEUROPATHOLOGY; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN LOCALIZATION; SKELETAL MUSCLE;

AGE OF ONSET; AMINOPHENOLS; APOPTOSIS; BUNGAROTOXINS; CALCIUM; CASPASES; CHOLINESTERASES; DNA MUTATIONAL ANALYSIS; ENZYME ACTIVATION; FAMILY HEALTH; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICROSCOPY, ELECTRON; MOTOR ENDPLATE; MUSCLES; MUTATION; MYASTHENIC SYNDROMES, CONGENITAL; NEUROLOGIC EXAMINATION; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROTEIN SUBUNITS; RECEPTORS, CHOLINERGIC;

EID: 1442353768     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10823     Document Type: Article

References (43)

1. Engel AG, Lambert EH, Mulder DM et al. A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann Neurol 1982;11:553-569.
2. Sine SM, Ohno K, Bouzat C, et al, Mutation of the acetylcholine receptor a subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity. Neuron 1995;15:229-239.
3. Milone M, Wang HL, Ohno K, et al. Slow-channel myasthenic syndrome caused by enhanced activation, desensitization, and agonist binding affinity attributable to mutation in the m2 domain of the acetylcholine receptor alpha subunit. J Neurosci 1997;17:5651-5665.
4. Gomez CM, Maselli R, Vohra B, et al. Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms. Ann Neurol 2002;51:102-112.
5. Gomez CM, Maselli R, Groshong JG, et al. Active calcium accumulation underlies severe weakness in a panel of mice with slow-channel syndrome. J. Neurosci 2002;22:6447-6457.
6. Engel AG, Ohno K, Milone M, et al. New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum Mol Genet 1996;5:1217-1227.
7. Croxen R, Newland C, Beeson D, et al. Mutations in different functional domains of the human muscle acetylcholine receptor alpha subunit in patients with the slow-channel congenital myasthenic syndrome. Hum Mol Genet 1997;6:767-774.
8. Piccini A, Malinow R. Transient oxygen-glucose deprivation induces rapid morphological changes in rat hippocampal dendrites. Neuropharmacology 2001;41:724-729.
9. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002;298:789-791.
10. Siso S, Puig B, Varea R, et al. Abnormal synaptic protein expression and cell death in murine scrapie. Acta Neuropathol (Berl) 2002;103:615-626.
11. Suzuki Y, Murakami N, Goto Y, et al. Apoptotic nuclear degeneration in Marinesco-Sjogren syndrome. Acta Neuropathol (Berl) 1997;94:410-415.
12. Yan C, Ikezoe K, Nonaka I. Apoptotic muscle fiber degeneration in distal myopathy with rimmed vacuoles. Acta Neuropathol (Berl) 2001;101:9-16.
13. Budihardjo I, Oliver H, Lutter M, et al. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999;15:269-290.
14. Brustovetsky N, Brustovetsky T, Jemmerson R, Dubinsky JM. Calcium-induced cytochrome c release from CNS mitochondria is associated with the permeability transition and rupture of the outer membrane. J Neurochem 2002;80:207-218.
15. Evans RH, Mitchell JF. Accumulation of calcium at the motor endplate. Br J Pharmacol 1971;43:433P-434P.
16. Gomez CM, Wollmann RL, Richman DP. Induction of the morphologic changes of both acute and chronic experimental myasthenia by monoclonal antibody directed against acetylcholine receptor. Acta Neuropathol 1984;63:131-143.
17. Gomez CM, Maselli R, Gundeck JE, et al. Slow-channel transgenic mice: a model of postsynaptic organellar degeneration at the neuromuscular junction. J Neurosci 1997;17:4170-4179.
18. Wijsman JH, Jonker RR, Keijzer R, et al. A new method to detect apoptosis in paraffin sections: in situ end-labeling of fragmented DNA. J Histochem Cytochem 1993;41:7-12.
19. Mangili F, Cigala C, Santambrogio G. Staining apoptosis in paraffin sections. Advantages and limits. Anal Quant Cytol Histol 1999;21:273-276.
20. Gomez CM, Ricardo Maselli BS, Lasalde J et al. A β subunit mutation in the acetylcholine receptor channel gate causes severe slow-channel syndrome. Ann Neurol 1996;39:717-723.
21. Engel AG, Lambert EH, Gomez MR. A new myasthenic syndrome with end-plate acetylcholinesterase deficiency, small nerve terminals, and reduced acetylcholine release. Ann Neurol 1977;1:315-330.
22. Hudson CS, Rash JE, Tiedt TN, Albuquerque EX. Neostigmine-induced alterations at the mammalian neuromuscular junction. II. Ultrastructure. J Pharmacol Exp Ther 1978;205:340-356.
23. Salpeter MM, Leonard JP, Kasprzak H. Agonist-induced postsynaptic myopathy. Neurosci Comment 1982;1:73-83.
24. Kawabuchi M. Neostigmine myopathy is a calcium ion-mediated myopathy initially affecting the motor end-plate. J Neuropathol Exp Neurol 1982;41:298-314.
25. Vohra BPS, Zayas R, Groshong J, et al. Focal reversible activation of apoptotic pathways in the slow-channel syndrome. Soc Neurosci Abstr 2001;21:432.
26. Chan SL, Mattson MP. Caspase and calpain substrates: roles in synaptic plasticity and cell death. J Neurosci Res 1999;58:167-190.
27. Nakagawa T, Zhu H, Morishima N, et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000;403:98-103.
28. Nakagawa T, Yuan J. Cross-talk between two cysteine protease families. Activation of caspase-12 by calpain in apoptosis. J Cell Biol 2000;150:887-894.
29. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-489.
30. Alam A, Cohen LY, Aouad S, Sekaly RP. Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells. J Exp Med 1999;190:1879-1890.
31. Hishita T, Tada-Oikawa S, Tohyama K, et al. Caspase-3 activation by lysosomal enzymes in cytochrome c-independent apoptosis in myelodysplastic syndrome-derived cell line P39. Cancer Res 2001;61:2878-2884.
32. Vaughan AT, Betti CJ, Villalobos MJ. Surviving apoptosis. Apoptosis 2002;7:173-177.
33. Deveraux QL, Roy N, Stennicke HR, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998;17:2215-2223.
34. Ruest LB, Khalyfa A, Wang E. Development-dependent disappearance of caspase-3 in skeletal muscle is post-transcriptionally regulated. J Cell Biochem 2002;86:21-28.
35. Deshmukh M, Kuida K, Johnson EM Jr. Caspase inhibition extends the commitment to neuronal death beyond cytochrome c release to the point of mitochondrial depolarization. J Cell Biol 2000;150:131-143.
36. Law PK, Saito A, Fleischer S. Ultrastructural changes in muscle and motor end-plate of the dystrophic mouse. Exp Neurol 1983;80:361-382.
37. Harriman DG. A comparison of the fine structure of motor end-plates in Duchenne dystrophy and in human neurogenic diseases. J Neurol Sci 1976;28:233-247.
38. Fahim MA. Rapid neuromuscular remodeling following limb immobilization. Anat Rec 1989;224:102-109.
39. Balice-Gordon R, Lichtman JW. In vivo observations of pre- and postsynaptic changes during the transition from multiple to single innervation at developing neuromuscular junctions. J Neurosci 1993;13:834-855.
40. Akaaboune M, Culican SM, Turney SG, Lichtman JW. Rapid and reversible effects of activity on acetylcholine receptor density at the neuromuscular junction in vivo. Science 1999;286:503-507.
41. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-634.
42. Mattson MP, Keller JN, Begley JG. Evidence for synaptic apoptosis. Exp Neurol 1998;153:35-48.
43. Mattson MP, Duan W. "Apoptotic" biochemical cascades in synaptic compartments: roles in adaptive plasticity and neurodegenerative disorders. J Neurosci Res 1999;58:152-166.